<img src="http://www.npicenter.com/images/MarcUllman.gif" border="0" align="left">Mr. Ullman speaks frequently on various regulatory matters at various events, including Virgo Publications' Natural Products Industry Supply Side West Trade Shows and the National Nutritional Foods Association's annual MarketPlace Convention. He also manages the FYI Newsletter highlighting legal and regulatory issues concerning the Natural Product Industry. <br><br>Marc is a partner in New York City based Ullman, Shapiro & Ullman, <a href="http://www.usulaw.com">www.usulaw.com</a>. You can contact him at Marc[at]usulaw.com<br><br><i>Please note that blog is not intended to provide or serve as legal advice of any kind, and that the reader should not rely on it for such advice.</i> http://www.npicommunity.com/Blogs/tabid/53/BlogId/1/Default.aspx en-US marc@usulaw.com contactus@npicenter.com Fri, 16 May 2008 17:37:50 GMT Fri, 16 May 2008 17:37:50 GMT http://backend.userland.com/rss Blog RSS Generator Version 3.1.20.17153 A common misconception seems to be that the strongest regulatory action the Food and Drug Administration will take against companies that market dietary supplements with blatant drug claims will be to issue a Warning Letter. A 33-count indictment handed down by a federal grand jury this week suggests otherwise. http://www.npicommunity.com/Blogs/tabid/53/EntryID/105/Default.aspx marc@usulaw.com http://www.npicommunity.com/Blogs/tabid/53/EntryID/105/Default.aspx#Comments http://www.npicommunity.com/Default.aspx?tabid=53&EntryID=105 Fri, 29 Feb 2008 20:50:00 GMT 0 http://www.npicommunity.com/DesktopModules/Blog/Trackback.aspx?id=105